Seminarios de la Fundación Espa?ola de Reumatología最新文献_第10页

Tratamiento farmacológico en la fibromialgia 纤维肌痛的药物治疗

Seminarios de la Fundación Espa?ola de Reumatología Pub Date : 2011-01-01 DOI: 10.1016/j.semreu.2010.05.003

Javier Rivera Redondo

引用次数: 6

Seminarios de la Fundación Espa?ola de Reumatología Pub Date : 2011-01-01 DOI: 10.1016/j.semreu.2011.01.001

引用次数: 0

Lupus eritematoso neonatal 新生儿红斑狼疮

Seminarios de la Fundación Espa?ola de Reumatología Pub Date : 2011-01-01 DOI: 10.1016/j.semreu.2010.06.002

Paula Aguilera Peiró , Asunción Vicente Villa , M. Antonia González-Enseñat

{"title":"Lupus eritematoso neonatal","authors":"Paula Aguilera Peiró , Asunción Vicente Villa , M. Antonia González-Enseñat","doi":"10.1016/j.semreu.2010.06.002","DOIUrl":"https://doi.org/10.1016/j.semreu.2010.06.002","url":null,"abstract":"<div><p>Neonatal lupus erythematosus (NLE) is an uncommon disease caused by transport of maternal autoantibodies against Ro, La and/or ribonucleoprotein (RNP) into the fetal circulation. These IgG antibodies cross the placenta and can potentially damage fetal tissue and cause the clinical manifestations of NLE.</p><p>NLE is more common in girls, has no racial association and can affect multiple organs. Cutaneous manifestations are present in 50% of patients and are clinically similar to the lesions of subacute lupus erythematosus. Patients with NLE have a higher risk of congenital heart block, a potentially fatal complication. Other, less frequent manifestations are hepatic and hematologic. Approximately half of all patients have cutaneous manifestations and the other half cardiac manifestations. Approximately 10% of patients have both cutaneous and cardiac manifestations. Cutaneous, hematological and hepatic manifestations are transient, healing at 6 months of age, due to the clearance of maternal autoantibodies. Congenital heart block is a permanent manifestation that usually requires pacemaker implantation.</p><p>Pregnant women with autoimmune diseases or anti-Ro or anti-La antibodies should be followed-up by ultrasound during pregnancy to detect any manifestations susceptible to treatment. Currently, there is no consensus on preventive treatment in high-risk patients or in those with a risk of recurrence. Equally, there is insufficient data to confirm the efficacy of currently available preventive treatments. What seems clear is that early detection of congenital heart block should be treated with fluorinated corticosteroids.</p></div>","PeriodicalId":101152,"journal":{"name":"Seminarios de la Fundación Espa?ola de Reumatología","volume":"12 1","pages":"Pages 15-20"},"PeriodicalIF":0.0,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.semreu.2010.06.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"92001542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 13

La reumatología líquida 液体风湿病学

Seminarios de la Fundación Espa?ola de Reumatología Pub Date : 2011-01-01 DOI: 10.1016/j.semreu.2010.11.002

Alejandro Olivé Marqués

引用次数: 0

Terapia biológica dirigida contra los linfocitos B en el lupus eritematoso sistémico 系统性红斑狼疮B淋巴细胞的生物治疗

Seminarios de la Fundación Espa?ola de Reumatología Pub Date : 2011-01-01 DOI: 10.1016/j.semreu.2010.06.003

Teresa Otón, Lucía Silva Fernández, Mónica Fernández Castro, José Luis Andreu

引用次数: 0

Síndrome del dedo azul 蓝手指综合症

Seminarios de la Fundación Espa?ola de Reumatología Pub Date : 2011-01-01 DOI: 10.1016/j.semreu.2010.04.002

Javier Narváez, María Marta Bianchi, Pilar Santo, Ivan Castellví

引用次数: 3

Tratamiento de la enfermedad por cristales de pirofosfato cálcico 用焦磷酸钙晶体治疗疾病

Seminarios de la Fundación Espa?ola de Reumatología Pub Date : 2010-10-01 DOI: 10.1016/j.semreu.2010.04.003

Mariano Andrés, Paloma Vela

引用次数: 2

Manifestaciones osteoarticulares de endocarditis 心内膜炎的骨关节表现

Seminarios de la Fundación Espa?ola de Reumatología Pub Date : 2010-10-01 DOI: 10.1016/j.semreu.2010.03.007

Violeta Bittermann, Anna Pros Simón

引用次数: 4

Reflexiones sobre el lupus eritematoso sistémico 对系统性红斑狼疮的反思

Seminarios de la Fundación Espa?ola de Reumatología Pub Date : 2010-10-01 DOI: 10.1016/j.semreu.2010.04.001

Josep Ordi Ros

引用次数: 0

¿Es necesaria la profilaxis antituberculosa en pacientes con enfermedades reumáticas inflamatorias tratados con glucocorticoides? 用糖皮质激素治疗的炎性风湿性疾病患者是否需要抗结核预防?

Seminarios de la Fundación Espa?ola de Reumatología Pub Date : 2010-10-01 DOI: 10.1016/j.semreu.2010.03.006

Javier Narváez, Pilar Santo Panero, María Marta Bianchi, Marc Díez García

{"title":"¿Es necesaria la profilaxis antituberculosa en pacientes con enfermedades reumáticas inflamatorias tratados con glucocorticoides?","authors":"Javier Narváez, Pilar Santo Panero, María Marta Bianchi, Marc Díez García","doi":"10.1016/j.semreu.2010.03.006","DOIUrl":"10.1016/j.semreu.2010.03.006","url":null,"abstract":"<div><p>Infections are one of the main causes of morbidity and mortality in patients with rheumatic inflammatory disorders. Among these infections, tuberculosis (TB) is one of the most significant, due to its prevalence and severity. Nevertheless, in general terms, the possibility of reactivation of latent TB is not usually considered in rheumatic patients treated with glucocorticoids and/or non-biological immunosuppressive agents. This lack of awareness among physicians treating these patients is a problem for the epidemiological control of TB infection in countries such as Spain where the prevalence of the disease is not inconsiderable. The available evidence suggests that the incidence of TB in patients receiving glucocorticoids for inflammatory rheumatic diseases is higher than in the general population (for example, the incidence is between 4 and 6 times higher in Spain).</p><p>One approach to prevent this complication would be to follow the recommendations of the American Thoracic Society and rule out latent TB infection in all patients who are to receive ≥15mg/day of prednisone or equivalent for more than 1 month before the treatment is started. When the results of a tuberculin test and/or interferon gamma release assays (IGRA) are positive, prophylactic treatment with isoniazid at a dose of 300mg/day for 9 months is recommended, provided that active TB has been ruled out.</p></div>","PeriodicalId":101152,"journal":{"name":"Seminarios de la Fundación Espa?ola de Reumatología","volume":"11 4","pages":"Pages 128-134"},"PeriodicalIF":0.0,"publicationDate":"2010-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.semreu.2010.03.006","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132222923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0